Curia is a global CDMO with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing. We offer services across Small Molecules, Generic APIs, and Biologics backed by deep scientific expertise and a robust global network of resources and capabilities.

Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners turn their ideas into real-world impact.

305 Church at North Hills Street 12th Floor Raleigh, NC 27609 USA

Steve Lavezoli is Curia’s Vice President of Biologics overseeing its discovery, development and manufacturing services. With a remarkable breadth of…

Biologics Expertise. Our end-to-end services for antibodies, proteins, enzymes, and mRNA vaccines and therapeutics. Drug Substance. Our Hopkinton, MA facility is ISO 13485:2016 certified and provides cGMP bulk drug substance manufacturing.

With the addition of LakePharma, Curia offers deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production.

Curia provides a complete suite of state-of-the-art instrumentation and techniques to characterize physicochemical and biopharmaceutical properties. Our experts work with you to identify appropriate experimentation and interpret results for the selection of suitable forms.

Fine Chemicals are highly pure, specialized chemical substances produced through complex synthesis processes. They serve as critical building blocks in industries such as pharmaceuticals, agriculture, and electronics, often designed for specific applications with precise specifications.

Curia offers end-to-end services for antibodies, proteins, enzymes, and mRNA vaccines and therapeutics.

Curia provides scientific expertise and state-of-the-art technologies to support the chemical development and cGMP manufacture of complex APIs, including its RSMs and intermediates, generics, potent and cytotoxic compounds, sterile APIs, steroids and controlled substances.